Pharmacists Raise Concerns Over Medicine Pricing and Pharmaceutical Industry Challenges
Representatives of the Pakistan Young Pharmacist Association (PYPA) and other stakeholders have expressed concerns about medicine pricing, pharmaceutical manufacturing, and the operating environment for multinational pharmaceutical companies in Pakistan.
The remarks were made during a press conference in Islamabad, where participants discussed recent developments in the country’s pharmaceutical sector.
PYPA Shares Industry Concerns
PYPA representatives stated that several multinational pharmaceutical companies have reduced or ended their operations in Pakistan over recent years. They linked these developments to changes in medicine pricing policies and broader business considerations.
Association officials also highlighted Pakistan’s dependence on imported pharmaceutical raw materials, noting that many local manufacturers rely on overseas suppliers for active ingredients and production inputs.
Discussion on Medicine Prices
During the briefing, PYPA representatives pointed to differences between medicine prices paid by government health departments through procurement contracts and retail prices available in the open market.
According to the association, government procurement often benefits from large-volume purchasing and competitive bidding, which can result in lower prices compared to retail sales.
The speakers suggested that medicine pricing policies should continue to be reviewed to improve affordability for patients.
Concerns About Medical Devices
PYPA representatives also discussed the importance of maintaining high quality standards for medical devices, including syringes and other healthcare products.
They emphasized the need for strong quality assurance systems and continued regulatory oversight to help ensure patient safety.
Call for Policy Review
Participants at the event urged policymakers to evaluate existing medicine pricing mechanisms and explore measures that balance patient affordability with the long-term sustainability of the pharmaceutical industry.
They also stressed the importance of encouraging local manufacturing and strengthening Pakistan’s pharmaceutical supply chain.
DRAP Responds
Responding to the concerns, Drug Regulatory Authority of Pakistan (DRAP) Chief Executive Officer Dr. Obaidullah Malik said it would not be accurate to conclude that multinational pharmaceutical companies left Pakistan solely because of government policies or regulatory decisions.
According to Dr. Malik, some companies entered joint ventures or restructured their businesses, while others adjusted their regional operations as part of broader global strategies.
Regarding differences between government procurement prices and retail market prices, he explained that pharmaceutical companies sometimes offer medicines to government hospitals at very competitive rates through bulk procurement arrangements. Such pricing strategies can help improve product availability in public healthcare facilities while supporting wider market acceptance.
Looking Ahead
The discussion highlights the ongoing debate over medicine pricing, pharmaceutical investment, and healthcare affordability in Pakistan.
Industry representatives and regulators agree that continued dialogue between policymakers, healthcare professionals, and pharmaceutical companies will be important to ensure access to quality medicines while supporting the growth of Pakistan’s healthcare sector.
